Answers are grounded in this paper and cite their sources.
Objective: To evaluate the realworld safety, and effectiveness of empagliflozin in Sri Lankan patients with Type-2 diabetes mellitus (T2DM).Methodology: This was a prospective, multicenter, observational cohort study conducted as post-marketing surveillance at two outpatient clinical sites in Sri Lanka from January 2023 to May 2025. Adults aged 18–65 years with T2DM, HbA1c 7–10%, eGFR >60 mL/min/1.73 m², and inadequate glycemic control despite oral antidiabetic therapy were enrolled. The decision to initiate empagliflozin (Empiget™) 10 mg once daily as add-on therapy was made independently by the treating physician as part of routine clinical care and was not assigned by the study protocol. Data were collected prospectively using an electronic case report form at baseline and at 1-, 3-, and six-months follow-up visits. A non-probability consecutive sampling technique was used. Ethical approval was obtained from the institutional ethics committee of the National Hospital of Sri Lanka, and written informed consent was obtained from all participants. Safety outcomes included adverse events, serious adverse events, and treatment discontinuation, while effectiveness outcomes included changes in HbA1c, fasting blood glucose, body weight, and blood pressure.Results: Among 246 patients (mean age 51.8 ± 9.2 years), empagliflozin was generally well tolerated. Adverse events were infrequent and occurred mainly during the early treatment period, most commonly mild hypoglycemia and genitourinary symptoms. Two serious adverse events were reported, both resulting in treatment discontinuation; neither was assessed as causally related to empagliflozin. No serious adverse events were observed at six months. Median HbA1c decreased from 8.9% to 7.4%, fasting blood glucose from 159 to 121 mg/dL, body weight decreased by approximately two kg, and both systolic and diastolic blood pressure showed modest reductions. Renal function parameters remained clinically stable throughout followup.Conclusion: In this realworld postmarketing surveillance study, empagliflozin 10 mg demonstrated a favorable safety and tolerability profile and was associated with improvements in glycemic control, body weight, and blood pressure over six months.
No takes yet. Share an insight, caveat, or question.
Sumanatilleke et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: